Observational Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Apr 21, 2017; 23(15): 2802-2810
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2802
Table 1 Baseline demographic and clinical characteristics of all subjects with normal alanine aminotransferase level
All (n = 155)HBeAg-positive (n = 86)HBeAg-negative (n = 69)
Age (yr)39.7 ± 9.942.9 ± 8.937.2 ± 9.9
Male, n (%)84 (54.2)52 (60.9)34 (48.8)
HBV DNA (logIU/mL)5.8 ± 2.14.3 ± 1.46.9 ± 1.9
WBC (109/mL)5.9 ± 3.15.9 ± 4.45.8 ± 1.5
PLT (109/mL)190.08 ± 62.9182.29 ± 57.7196.3 ± 66.5
ALT (U/L)26.0 ± 8.725.0 ± 9.226.8 ± 8.1
AST (U/L)24.6 ± 6.624.1 ± 6.125.1 ± 7.0
ALP (U/L)68.1 ± 20.167.1 ± 17.268.9 ± 22.2
GGT (U/L)21.8 ± 14.621.1 ± 11.922.3 ± 16.5
TB (g/L)13.6 ± 6.713.6 ± 7.513.6 ± 6.1
PT (s)11.4 ± 1.111.4 ± 1.011.4 ± 1.4
TT (s)19.1 ± 1.718.8 ± 1.819.3 ± 1.5
A/G ratio1.7 ± 0.41.8 ± 0.41.7 ± 0.4
Cr (μmol/L)70.2 ± 14.670.0 ± 15.270.4 ± 14.2
TBA (μmol/L)8.7 ± 14.16.3 ± 6.010.7 ± 17.9
GLB (g/L)27.2 ± 4.326.9 ± 4.127.5 ± 4.4
ALB (g/L)45.6 ± 4.046.7 ± 4.044.5 ± 3.9
Table 2 Demographic and clinical characteristics of carriers with and without significant liver changes
Significant necroinflammation (n = 42)No significant necroinflammation (n = 113)P valueSignificant fibrosis (n = 24)No significant fibrosis (n = 131)P value
Age (yr)40.0 ± 9.339.7 ± 10.10.85441.3 ± 10.339.5 ± 9.80.416
Male, n (%)13790.41720230.505
HBV DNA (logIU/mL)6.0 ± 2.05.7 ± 2.20.3685.6 ± 2.05.8 ± 2.10.733
WBC (109/mL)6.2 ± 5.75.7 ± 1.40.5604.9 ± 1.26.0 ± 3.30.117
PLT (109/mL)170.2 ± 58.4197.5 ± 63.20.016150.3 ± 51.1197.4 ± 62.30.001
ALT (U/L)29.6 ± 8.824.6 ± 8.30.00129.7 ± 8.025.3 ± 8.60.116
AST (U/L)27.5 ± 6.023.6 ± 6.00.00427.8 ± 6.424.1 ± 6.60.012
ALP (U/L)70.4 ± 25.067.2 ± 17.90.46378.7 ± 29.466.1 ± 17.30.004
GGT (U/L)25.8 ± 19.420.3 ± 12.10.42333.9 ± 25.419.6 ± 10.30.000
TB (g/L)14.1 ± 6.913.4 ± 6.70.53816.0 ± 7.213.2 ± 6.60.057
PT (s)11.6 ± 1.011.3 ± 1.20.10011.7 ± 1.011.3 ± 1.20.152
TT (s)19.4 ± 1.719.0 ± 1.60.23519.2 ± 1.819.1 ± 1.60.776
A/G ratio1.8 ± 0.41.7 ± 0.40.1731.7 ± 0.31.8 ± 0.40.700
Cr (μmol/L)66.7 ± 14.671.5 ± 14.40.07071.8 ± 14.269.9 ± 14.70.557
TBA (μmol/L)9.0 ± 8.18.7 ± 15.70.90016.8 ± 30.57.3 ± 7.40.002
GLB (g/L)26.5 ± 4.327.5 ± 4.20.18327.3 ± 3.927.2 ± 4.30.915
ALB (g/L)45.1 ± 3.445.8 ± 4.20.33544.2 ± 3.545.9 ± 4.10.058
Table 3 Univariate and multivariate logistic regression analysis of risk factors of significant necroinflammation and fibrosis
Significant necroinflammation
Significant fibrosis
Univariate
Multivariate
Univariate
Multivariate
OR (95%CI)P valueOR (95%CI)P valueOR (95%CI)P valueOR (95%CI)P value
Age (yr)0.994 (0.949, 1.042)0.8121.003 (0.968, 1.040)0.120
Male1.351 (0.530, 3.440)0.5291.346 (0.656, 2.760)0.418
HBV-DNA (logIU/mL)1.249 (0.978, 1.595)0.0751.078 (0.910, 1.276)0.385
WBC (109/mL)0.907 (0.648, 1.269)0.5690.611 (0.359, 1.039)0.069
PLT (109/mL)0.990 (0.980, 0.999)0.030.692 (0.646, 0.709)0.0030.688 (0.641, 0.723)0.008
ALT (U/L)1.081 (1.020, 1.147)0.0091.059 (0.985,1.139)0.121
AST (U/L)1.590 (1.502, 1.651)0.00021.682 (1.613, 1.704)0.0071.091 (1.006, 1.185)0.036
ALP (U/L)1.018 (0.994, 1.042)0.1391.051 (1.015, 1.089)0.006
GGT (U/L)1.021 (0.993, 1.050)0.1511.524 (1.491, 1.587)0.0071.453 (1.406, 1.511)0.036
TB (g/L)0.988 (0.921, 1.059)0.7231.025 (0.945, 1.112)0.547
PT (s)1.683 (0.941, 3.009)0.0792.022 (1.012, 4.042)0.083
TT (s)1.235 (0.945, 1.615)0.1221.294 (0.948, 1.768)0.105
A/G ratio2.053 (0.570, 7.393)0.2710.580 (0.099, 3.394)0.546
Cr (μmol/L)0.974 (0.941, 1.009)0.1431.000 (0.957, 1.046)0.997
TBA (μmol/L)1.063 (0.998, 1.131)0.0571.065 (1.001, 1.133)0.048
GLB (g/L)0.953 (0.862, 1.053)0.3451.001 (0.877, 1.143)0.986
ALB (g/L)0.931 (0.836, 1.036)0.1910.923 (0.805, 1.058)0.250